Targeting the PI3K signaling pathway in cancer
Top Cited Papers
- 28 February 2010
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Genetics & Development
- Vol. 20 (1), 87-90
- https://doi.org/10.1016/j.gde.2009.11.002
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK InhibitionCancer Research, 2009
- Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for ResistanceCancer Research, 2008
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K MutationsCancer Research, 2008
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsJCI Insight, 2008
- Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 MimeticsPLoS Medicine, 2007
- BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR MutationsPLoS Medicine, 2007
- Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung AdenocarcinomasPLoS Medicine, 2007
- Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in MiceCell, 2007